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OBJECTIVE—Diabetes is an independent risk factor for stroke.
However, the underlying mechanism of how diabetes confers that
this risk is not fully understood. We hypothesize that secretion of
neurotrophic factors by the cerebral endothelium, such as brain-
derived neurotrophic factor (BDNF), is suppressed in diabetes.
Consequently, such accrued neuroprotective deﬁcits make neu-
rons more vulnerable to injury.
RESEARCH DESIGN AND METHODS—We examined BDNF
protein levels in a streptozotocin-induced rat model of diabetes
by Western blotting and immunohistochemistry. Levels of total
and secreted BDNF protein were quantiﬁed in human brain
microvascular endothelial cells after exposure to advanced
glycation end product (AGE)-BSA by enzyme-linked immunosor-
bent assay and immunocytochemistry. In media transfer experi-
ments, the neuroprotective efﬁcacy of conditioned media from
normal healthy endothelial cells was compared with AGE-treated
endothelial cells in an in vitro hypoxic injury model.
RESULTS—Cerebrovascular BDNF protein was reduced in the
cortical endothelium in 6-month diabetic rats. Immunohistochem-
ical analysis of 6-week diabetic brain sections showed that the
reduction of BDNF occurs early after induction of diabetes.
Treatment of brain microvascular endothelial cells with AGE
caused a similar reduction in BDNF protein and secretion in an
extracellular signal–related kinase-dependent manner. In media
transfer experiments, conditioned media from AGE-treated endo-
thelial cells were less neuroprotective against hypoxic injury be-
cause of a decrease in secreted BDNF.
CONCLUSIONS—Taken together, our ﬁndings suggest that
a progressive depletion of microvascular neuroprotection in
diabetes elevates the risk of neuronal injury for a variety of
central nervous system diseases, including stroke and neuro-
degeneration. Diabetes 60:1789–1796, 2011
D
iabetes mellitus signiﬁcantly elevates the risk
for a variety of neurologic diseases, including
stroke (1–3). Age-adjusted incidence rates sug-
gest that diabetic patients are three times more
likely to have a stroke compared with nondiabetic patients,
a disparity that is seen across multiple racial/geographic
groups (4–7). In addition, diabetes is associated with more
severe strokes, in-hospital mortality, and slower recovery
compared with nondiabetic individuals (8–11). Diminished
cognitive abilities are found in patients with type 1 diabetes,
whereas type 2 diabetes is known to also affect learning
and memory (12,13). Many population-based studies have
found an association between diabetes and an increased
risk of developing Alzheimer’s disease and vascular de-
mentia (14,15).
How does diabetes confer this elevated risk for pro-
gressive neuronal injury? In this study, we explored the
hypothesis that cerebrovascular neurotrophic protection is
reduced in diabetes, thereby causing progressive neuronal
dysfunction. Neurons do not exist in isolation, and sym-
biotic trophic coupling mechanisms exist between cere-
bral microvasculature and neurons (16–21). Recent studies
suggest that endothelial cells serve endocrine functions in
the brain by secreting neuroprotective factors, such as
brain-derived neurotrophic factor (BDNF) (22,23). In this
study, we investigate the implications of decreased cere-
brovascular BDNF–mediated neurotrophic function in di-
abetes in an effort to examine the role of vascular
dysfunction in diabetes complications of the brain.
RESEARCH DESIGN AND METHODS
Diabetic rat model of diabetes. All experiments were performed following
an institutionally approved protocol in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory Animals. Diabetes was
induced with streptozotocin (STZ) (57.5 mg/kg body wt) dissolved in citrate
buffer, pH 4.5, through a tail-vein injection. Induction of diabetes was veriﬁed
after 3 days, and rats with blood glucose concentrations .250 mg/dL were
included in these studies. Body weight was measured three times per week,
and 3–4 units of neutral protamine Hagedorn insulin (0.5 IU) was administered
subcutaneously, as needed, to prevent weight loss and ketosis. The diabetic
rats were killed, and brains were collected after perfusion along with age-
matched controls. Cerebral cortex was dissected from whole brains for
microvessel-enriched fractions and stored at 280°C before fraction prepara-
tion. At the time of death, blood was obtained by cardiac puncture for esti-
mation of glycosylated hemoglobin (Glyco-Tek Afﬁnity Kit, Helena Laboratories,
Beaumont, TX).
Brain microvessel preparation by dextran gradient centrifugation. Iso-
lation of microvessel-enriched fractions from rat tissue was performed as
described by Wu et al. (24) and Galea and Estrada (25). Brieﬂy, brain tissues
were collected from rats after PBS reperfusion. The cortical gray matter was
dissected and rolled on ﬁlter paper to remove the large blood vessels and then
homogenized with PBS and centrifuged. After washing with PBS, the pellet
was resuspended in four volumes of 18% dextran and centrifuged at 1,500g for
20 min. The new pellet was saved, and the remaining tissue was reprocessed
twice similarly. All three pellets were pooled, washed again with PBS, and
lysed in lysis buffer (Cell Signaling Technology, Danvers, MA) with proteinase
inhibitors for immunoblotting. Microvessel-enriched fractions in all experi-
ments were not pooled and were derived from a single animal cortex.
Immunochemical procedures. For immunohistochemistry, whole brain
sections (2-mmthick) werepreparedfrom frozen ratbrains.Sections werekept
frozen at 280°, after which they were air-dried, ﬁxed in ice-cold acetone,
blocked with 5% BSA, and probed with an anti-BDNF rabbit polyclonal anti-
body (Millipore, Billerica, MA). For immunocytochemistry, cells were seeded
onto gelatin-coated glass coverslips and maintained in complete media. Cells
were ﬁxed in ice-cold ethanol, rinsed with 13 PBS, blocked with 5% BSA, and
probed with an anti-BDNF antibody (Millipore) or anti-CD31 antibody (BD
Biosciences, San Diego, CA).
Cell culture and treatments. Primary human brain microvessel endothelial
cells were purchased from Cell Systems Corporation (Kirkland, WA), mostly
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ORIGINAL ARTICLEderived from a heterogenous mix of rapidly autopsied human brains obtained
within a few hours after death. We used cells between passages 5 and 10 at
;80% conﬂuence for all studies. The endothelial cells were maintained in
complete MCDB-131 medium with L-glutamine, 1 g/L D-glucose, and 10% FBS
(Vec Technologies, New York, NY), and seeded onto human gelatin-coated
plates for all experiments. Primary mouse embryo cortex neurons were
seeded on poly-D-lysine–coated plates and maintained with Neurobasal media
plus 2% B27, 0.5 mmol/L glutamine, and penicillin/streptomycin (Invitrogen,
Carlsbad, CA). Neurons were used for conditioned media-transfer experi-
ments between days 8 and 10. All treatments with BSA, advanced glycation
end product (AGE)-BSA, and the MEK/extracellular signal–related kinase
(ERK) inhibitor U0126 were performed in 1% serum MCDB media supple-
mented with L-glutamine and 4.5 g/L D-glucose. AGE-BSA and U0126 were
procured from Calbiochem (San Diego, CA).
ELISAs, cytoxicity assay, immunoblotting. The ELISA kit for BDNF was
obtained from Promega (Madison, WI). MTT assay and LIVE/DEAD viability/
cytotoxicity assay were used to assess cell death. For immunoblotting, the
primary antibodies were obtained from Cell Signaling Technology (BDNF
antibody), Biomol/Enzo Life Sciences (neuron-speciﬁc enolase; Plymouth
Meeting, PA), and Promega (total and pERK antibodies). All secondary anti-
bodies were obtained from Pharmacia (New York, NY).
Hypoxia and media transfer experiments. Primary endothelial cells were
treated with or without AGE-BSA for 48 h, before the conditioned media were
transferred to neurons. Conditioned media collected from endothelial cells
were transferred to primary mouse cortical neurons cultured overnight in
serum-free Neurobasal media minus B27 and antibiotics. Neurons were then
placed in a hypoxic chamber (Billups-Rothenberg, Inc., Del Mar, CA). The
chamber with cells was perfused with mixed atmosphere (90% nitrogen, 5%
carbondioxide,and5%hydrogen)for30minandthensealedandplacedat37°C
for indicated time periods of hypoxia. After 48 h, cells were removed from the
chamber and changed to fresh Neurobasal serum-free media, maintained in
a regular CO2 incubator for reoxygenation. Control cultures were incubated
under normoxic conditions for equivalent durations.
Statistical methods. Quantitative data from all experiments were analyzed
using the JMP-IN statistical software 7.0 (SAS Institute Inc., Cary, NC). Student
t test was performed for two-group comparisons. One-way ANOVA was per-
formed for multiple group comparisons followed by Tukey-Kramer tests for
pairwise comparisons. Differences reaching P , 0.05 were considered sig-
niﬁcant.
RESULTS
BDNF expression is reduced in diabetic rat brain
endothelium in vivo. Diabetes was induced in adult male
SD rats by STZ injection. After 6 months of diabetes, the
diabetic rats showed lower body weight and higher glyco-
hemoglobin levels than the age-matched nondiabetic con-
trol rats (Table 1).
Diabetic and nondiabetic rat cerebral cortices were
extracted, and microvessel-enriched fractions were pre-
pared for Western blotting. These fractions were positive
TABLE 1
Body weight and glycated hemoglobin of study rats (6 months’
diabetes duration)
N
Body weight
at start (g)
Body weight
at end (g)
Glycated
hemoglobin (%)
Nondiabetic 4 260.5 6 48.5 606.7 6 58.1 4.2 6 0.22
Diabetic 4 253.2 6 50.9 385.7 6 30.9 14.2 6 1.6*
Percentage of glycated hemoglobin in blood samples of 6-month di-
abetic rats was signiﬁcantly higher than in age-matched nondiabetic
rats. Values are mean 6 SD. Statistical analysis was performed with
unpaired t test. *P , 0.05 compared with nondiabetic rats.
FIG. 1. BDNF protein is reduced in microvessel-enriched fractions of the diabetic rat cortex. Representative Western blots showing signiﬁcant
enrichment of endothelial components in microvessel-enriched fractions, as demonstrated by high levels of vascular endothelial-cadherin protein
(A) and low levels of neuron-speciﬁc enolase and glial ﬁbrillary acidic protein (B). BDNF levels are reduced in the microvessel-enriched fractions
of 6-month diabetic rat cortex compared with age-matched nondiabetic rat cortex. TATA-binding protein is used as loading control (C). Densi-
tometric quantitation of Western blots show that BDNF levels in microvessel-enriched brain fractions are signiﬁcantly higher in age-matched
nondiabetic rat cortex compared with 6-month diabetic rat cortex (D). *P < 0.05 between control and diabetic rat cortices, N = 4 per group. GFAP,
glial ﬁbrillary acidic protein; HBEC, human brain endothelial cell; NSE, neuron-speciﬁc enolase; TBP, TATA-binding protein; VE, vascular endo-
thelial.
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thelial identity (Fig. 1A), whereas staining for neuron-
speciﬁc enolase and glial ﬁbrillary acidic protein was
weak, suggesting that they were not overly contaminated
with neurons or astrocytic components (Fig. 1B). A 16-kDa
band corresponding to bioactive BDNF protein was de-
tected in all fractions. BDNF levels were signiﬁcantly re-
duced in microvessel-enriched fractions from diabetic rats
compared with nondiabetic rats (Fig. 1C and D). To con-
ﬁrm our ﬁndings, 6-week normal and diabetic rat brains
were sectioned and prepared for immunohistochemistry.
BDNF staining was observed in the blood vessels of the
cortex. BDNF levels appeared to be lower in diabetic en-
dothelium compared with normal vessels (Fig. 2).
AGE-BSA treatment decreases BDNF levels in brain
endothelial cells. Our in vivo data suggested that endo-
thelial BDNF was suppressed in diabetic endothelium. To
assess the mechanisms involved, we switched to an in vitro
experimental model using AGE-BSA to mimic endothelial
stress triggered during diabetes. Human microvascular
brain endothelial cells were incubated with AGE-BSA for
48 h in serum-free media. This treatment caused a change
in cell morphology, with changes in cell shape and loss of
cell–cell contact (Fig. 3A).
After 48 h, BDNF protein levels in the cell lysates were
assessed by Western blotting. AGE-BSA clearly induced
a dose-dependent reduction in BDNF levels (Fig. 3B).
Compared with normal BSA controls, BDNF levels were
signiﬁcantly reduced in the AGE-BSA–treated endothelial
cells (Fig. 3C and D). No changes in cell viability were
noted, suggesting that these reductions in BDNF were not
indirectly caused by nonspeciﬁc cytotoxicity (Fig. 3E).
Immunostaining conﬁrmed our Western blot ﬁndings. In
normal human brain endothelial cells, cytoplasmic BDNF
staining was observable in the perinuclear zone and in
vesicles being trafﬁcked to the plasma membrane (Fig. 4A).
In AGE-BSA–treated endothelial cells, there was a clear
reduction in BDNF staining compared with untreated con-
trols (Fig. 4A). Consistent with these immunostaining
observations, AGE-BSA affected the secretion of BDNF into
extracellular space. Standard enzyme-linked immunosor-
bent assays conﬁrmed that conditioned media from brain
endothelial cells contained BDNF. AGE-BSA–treated endo-
thelial cells showed a signiﬁcant decrease in secreted BDNF
compared with untreated cells or controls treated with
normal BSA (Fig. 4B).
AGE-BSA–induced reduction of BDNF is dependent
on ERK/MAP kinase signaling. AGEs can trigger many
intracellular signaling pathways. Because ERK/mitogen-
activated protein (MAP) kinase is one of the major mecha-
nisms that allow endothelial cells to respond to extracellular
stimuli, we asked whether this signaling pathway might be
involved in the phenomenon of AGE-BSA–induced down-
regulation of BDNF. Human brain endothelial cells were
exposed to AGE-BSA for 48 h, and then cell lysates were
probed for changes in ERK and phospho-ERK. Levels of
phospho-ERK were signiﬁcantly elevated in AGE-BSA–
treated cells with no change in total ERK (Fig. 5A and B).
Next, we tested the effects of the potent MEK/ERK inhibitor
U0126 to provide pharmacologic evidence of causality. As
expected, AGE-BSA decreased BDNF expression in brain
endothelial cells. Blockade of ERK signaling with U0126
decreased phospho-ERK levels and signiﬁcantly prevented
this AGE-BSA–induced suppression of BDNF (Fig. 5C
and D). Concomitantly, blockade of ERK signaling also in-
terfered with the ability of AGE-BSA to decrease the secretion
of BDNF into conditioned media (Fig. 5E). Taken together,
these data suggest that the ability of AGE-BSA to suppress
endothelial BDNF requires ERK/MAP kinase signaling.
BDNF-mediated neuroprotection is lost after AGE-
BSA treatment in brain endothelial cells. Because
AGE-BSA decreased the production of BDNF, we hy-
pothesized that this would mean that “diabetic” endothe-
lium would lose the ability to trophically protect neurons.
First, we conﬁrmed that AGE-BSA does not directly kill
neurons (Fig. 6A). Next, media transfer experiments were
performed whereby brain endothelial-conditioned media
were added to primary mouse neurons subjected to hyp-
oxia for 24 h. As expected, hypoxia killed neurons (Fig. 6B
and C), and, as previously reported, conditioned media
from normal healthy brain endothelial cells were signiﬁ-
cantly neuroprotective (Fig. 6B and C). In contrast, con-
ditioned media from AGE-BSA–treated endothelial cells
were no longer neuroprotective (Fig. 6A and B), consistent
with their reduction in BDNF levels. Addition of exoge-
nous BDNF back into the culture media restored pro-
tection and decreased neuronal death (Fig. 6B and C).
Finally, the role of ERK signaling in the pathway was
conﬁrmed by U0126 experiments. Blockade of ERK with
U0126 not only prevented endothelial BDNF suppression
(Fig. 5D) but also restored neuroprotection (Fig. 6C).
DISCUSSION
Symptomatic strokes caused by large artery disease have
garnered much attention in cerebrovascular investigations.
FIG. 2. BDNF expression is reduced in the diabetic brain endothelium.
Representative images of cortical sections (2-mm thick) from 6-week
diabetic and age-matched nondiabetic rats immunostained for BDNF.
Blood vessels (arrows) are visualized by CD31 staining (left). Cortex
microvessels from a diabetic rat show decreased BDNF immunoﬂuo-
rescence when compared with those of a nondiabetic rat (right).
Magniﬁcation 403. (A high-quality digital representation of this ﬁgure
is available in the online issue.)
D. NAVARATNA AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, JUNE 2011 1791In contrast, small vessel dysfunction in the deeper layers of
the brain cortex has received less emphasis, even though
this comprises approximately one-third of all symptomatic
strokes (26). This problem may be especially important for
diabetic patients who present a higher incidence of lacunar
stroke with recursive hemorrhagic episodes (6,27). Al-
though the effects of acute hyperglycemia on brain injury
are well documented in global and focal ischemia models
(28), there is a bigger need to ﬁrst study the effects of long-
term diabetes on the brain. Emerging studies support the
notion that preemptive vascular disease in diabetes affects
ischemic brain injury before, during, and after stroke by
modifying adaptive neovascularization responses and post-
ischemic tissue remodeling (29,30). However, there is little
clarity on baseline changes in cerebrovascular function in
diabetes and the relative contribution of major diabetic
stressors to cerebrovascular disease. Our ﬁndings suggest
that cellular stress from AGEs leads to reduced cerebro-
vascular secretion of BDNF, a major mediator of neuro-
protection.
A large body of evidence suggests that AGEs are central
mediators of almost all diabetic vascular complications (31–
34), beyond effects of prolonged hyperglycemia. A marked
increase in deposition and accumulation of protein glyca-
tion end products in blood vessels has been linked to cor-
responding neuronal impairment, cognitive dysfunction,
and dementia in several streams of investigation. In human
brain tissue, increased cerebrovascular carboxymethyl
lysine-AGE staining was observ e di np e o p l ew i t hd i a b e t e s
and clinical dementia, strengthening the argument that
vascular accumulation of AGEs correspond with clinical
presentations of neuronal injury (35). Notably, an accu-
mulation of AGEs in microvessels along with its receptor,
RAGE, is reported to drive microvascular AGE-RAGE–
mediated chronic inﬂammation in Alzheimer pathologies
(36). In addition, administration of AGE-BSA signiﬁcantly
increased cerebral infarct size in a rat model of focal ce-
rebral ischemia, suggesting that increased severity of stroke
associated with diabetes might be characterized by AGE
accumulation (37). In our study, treatment of primary brain
microvascular cells with AGE-BSA signiﬁcantly suppressed
the production of BDNF via ERK/MAP kinase signaling
pathways, whereas treatment with high glucose alone did
not (data not shown). Subsequently, because of the loss
of BDNF, endothelial cells exposed to AGE-BSA were no
longer able to protect neuronal cultures against hypoxic
injury. Although our in vitro model of AGE-BSA treatment
cannot be equated to in vivo diabetic conditions, it is
useful in assessing the direct contribution of AGEs to
neurotrophic reduction observed in vivo.
We chose to study BDNF levels at 6 weeks and 6 months
of diabetes as a suitable time window to characterize early
chronic injury in diabetes. Several studies have focused
on this early duration of diabetes to capture adaptive
FIG. 3. AGE-BSA treatment decreases BDNF levels in endothelial cells. A: Cell morphology is altered by 48-h AGE-BSA treatment. Cells show
decreased cell–cell contact and changes in cell shape. B: Representative Western blot shows that BDNF protein is reduced in cell lysates in a dose-
dependent manner after AGE treatment (10–100 mg/mL). TATA-binding protein is used as loading control. C: Representative Western blot shows
that exposure to 50 mg/mL of AGE-BSA reduced BDNF protein. Treatment with 50 mg/mL of unglycated BSA did not alter BDNF levels. Gel sections
were derived from a single representative Western blot. D: Quantitative densitometry showing that AGE-BSA–treated endothelial cells expressed
signiﬁcantly lower BDNF compared with untreated cells or cells treated with normal BSA. *P < 0.05 between untreated and AGE-BSA treatment,
N = 3 per group. E: AGE-BSA treatment (50 mg/mL) did not cause overt cytotoxicity as measured by the MTT assay, N = 3 per group. TBP, TATA-
binding protein.
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of endothelial cells and smooth muscle cells in cerebral
cortical arterioles was observable between 14 and 16 weeks
in the STZ model of diabetes (38). Increased capillary
basement membrane thickening, pericyte degeneration, and
decreased cortical capillary density were observed between
4 and 8 months of diabetes in the rats with STZ-induced
diabetes (39). A dramatic loss of neocortical neurons co-
incident with marked shortening of capillary network in
the neocortical tissue was observed after 1 year of diabetes
in the rat with STZ-induced diabetes by morphometric
quantiﬁcation (40). Taken together, a progressive depletion
of microvascular neurotrophic support seems imminent
in the diabetic brain. Reduced cerebrovascular BDNF
support, as observed in our study, could be a molecular
mechanism underlying neuronal dysfunction observed in
previous studies. Our media transfer experiments with
cortical embryonic neurons only provide proof of concept
on how such a deﬁcit might render neurons more vulner-
able to a second insult. This cannot be unequivocally ex-
trapolated, as yet, to BDNF dependence in the adult
diabetic brain directly. Nevertheless, it is now accepted
that BDNF is not only important for neural development, it
(or other trophic factors) contributes to adult brain ho-
meostasis as well. BDNF is required for survival of both
developing and adult DRG neurons (41). In vivo blockade
of trk receptors leads to widespread neuronal death in
adult mouse brains (42), and a conditional BDNF knock-
out mouse shows disrupted striatal neuron survival and
function (43). In this context, our data provide a potential
mechanism that may underlie the increased neuronal vul-
nerability of diabetic brains.
Endothelial cells are a major source of neuroprotective
BDNF protein in the brain (44–46). In addition, BDNF has
unique systemic and metabotrophic functions (47). Our
ﬁndings also may be consistent with the clinical disease
literature. Cerebral output and plasma levels of BDNF are
reduced in individuals with type 2 diabetes (48–50). Be-
cause these changes occur in an insulin-dependent manner,
it suggests that glycemic memory and BDNF status might
be linked (49). In our study, we found that BDNF protein
levels were reduced in microvessel-enriched fractions of
6-month diabetic rat cortices and that BDNF protein ex-
pression was decreased in the diabetic endothelium. Al-
though these ﬁndings point to endothelial dysfunction as
a mechanism for loss of neuroprotection in the diabetic
brain, they remain reductionist, given that other cell types
can secrete BDNF in the brain. The existence of compen-
satory mechanisms in the parenchyma that make up for
the microvascular deﬁcit cannot be ruled out. To dissect
the singular contribution of the endothelium, targeted si-
lencing of the BDNF gene by conditional knockout experi-
ments or by small interfering RNA strategy will be required.
Nevertheless, there is reason to believe that in the deeper
cortical layers of the brain, with a high vessel-to-neuron
ratio, the endothelia serve as major life-supporting reposi-
tories of trophic growth factors.
Our data suggest that BDNF is a leading candidate of
cerebrovascular trophic coupling mechanisms. However,
the autocrine and paracrine functions of brain endothe-
lium are likely to include many trophic signals. Further
investigation is required to dissect the interactions with
other neurotrophic factors. The diabetes-induced decrease
of BDNF in cerebral microvessels seems to be mediated by
AGEs via activation of the ERK signaling pathway. These
ﬁndings are consistent with known receptor-mediated
effects of AGEs; however, nonreceptor-mediated effects of
AGEs cannot be ruled out, and more investigation is re-
quired to demonstrate a direct involvement of RAGE in
this pathway. Although our in vitro model of AGE-BSA
treatment cannot be equated to in vivo diabetic conditions,
it is useful in assessing the direct contribution of AGEs to
neurotrophic reduction observed in vivo.
In conclusion, our study identiﬁed a vascular mecha-
nism that may explain why diabetes increases risk for
neurologic injury such as stroke. Strategies to preserve
neurovascular trophic coupling mechanisms may lead to
the development of novel preventive neuroprotective
therapy in diabetes.
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